Rare Disease

Despite the rarity of each disease, rare diseases affect many patients worldwide.

There are more than 7,000 known rare diseases. Most of them are chronic, debilitating, or even life-threatening. More than half affect children. These diseases are characterized by a broad diversity of disorders and symptoms that vary not only from disease to disease, but also from patient to patient.

Rare diseases affect approximately 300 million patients worldwide. Due to unspecific symptoms and suboptimal awareness, the journey to the right diagnosis takes on average 6 to 8 years and all too often several mis-diagnoses unfortunately occur along the way. Shortening this diagnostic journey can improve quality of life, help patients and their families to understand their disease, and avoid unnecessary interventions. Earlier diagnosis is also crucial in providing more time for efficacious therapeutic interventions before irreversible damage – and working in this area with healthcare professionals is a core responsibility for Swixx.

The Rare diseases therapeutic area is a heritage focus of Swixx BioPharma. At Swixx we are proud to emphasize that our company enables the treatment of a large number of rare diseases - almost twenty. Swixx experts have extensive knowledge and a long-term history of achieving successful results in enabling patients’ access to the modern medicines of our partners, helping them live better lives.  Swixx partners with the following innovative companies in this therapeutic area: AstraZeneca/Alexion, BioCryst, Blueprint Medicines, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Otsuka, PTC and Sanofi.

Patient in Focus

At Swixx, patient care is at the heart of what we do. We see ourselves and aspire to be patients’ reliable partners throughout the healthcare cycle, by supporting education and diagnosis as well as helping the local healthcare community achieve better access to our partners' innovative medicines.  In this journey, we strive to support the patient community through numerous partnerships.

Facing and coping with a rare diagnosis can be challenging for patients and their caregivers. Through Swixx’s project called “My Rare Disease Journey,” we tried to showcase rare disease patients’ personal experiences, views and insights. We were privileged to collaborate with several Patient Advocacy Organizations – as part of their effort to raise awareness, understanding and early diagnosis of rare diseases.

From Rare to Resilient

My Journey with Pompe Disease: A Tale of Resilience and Triumph

My Rare Journey

Navigating Motherhood with Gaucher’s Disease

My Rare Journey with Gaucher disease

Boris Krizman, Croatia

My Rare Journey with Fabry disease

Matjaž, Slovenia

Dragana and Vanja's Rare Journey with Pompe Disease

Dragana and Vanja, Serbia

Iskra and Diyan’s Rare Journey with X-Linked Hypophosphatemia

Iskra and Diyan, Bulgaria

Nicoleta and Narcis’s Rare Journey with X-Linked Hypophosphatemia

Nicoleta & Narcis, Romania

Mihaela's Rare Journey with Hereditary Angioedema

Mihaela, Croatia

Diana's Rare Journey Acid SphingoMyelinase Deficiency

Diana, Croatia

Vesna's Rare Journey with Gaucher disease

Vesna, North Macedonia

Marija's Rare Journey with X-Linked Hypophosphatemia

Marija Milovanović, Serbia

Lucie's Rare Journey with Dravet Syndrome

Lucie (and her family story), Czech Republic

Created in collaboratrion with Epicana z.ú.

World Rare Disease Day 2025: Swixx Biopharma’s Commitment to Empowering the Rare Disease Community

Swixx Footprint in Rare

February 28th, 2025

At Swixx Biopharma, the Rare Diseases therapeutic area has always been at our core, reflecting our commitment to improving the lives of people affected by rare diseases. With nearly twenty innovative therapies from our esteemed partners, including AstraZeneca/Alexion, BioCryst, Ipsen, Jazz Pharmaceuticals, Krystal, Kyowa Kirin, Otsuka, PTC, and Sanofi, Swixx is proud to enable treatment options for numerous rare diseases that continue to be underserved globally.

  • BluePrint
  • Jazz Pharmaceuticals
  • Norgine
  • SeaGen
  • Otsuka
  • Bristol Myers
  • Sanofi
  • UPSA
  • GE Healthcare
  • Vifor
  • Gilead
  • Amgen
  • Alcon
  • Merz
  • Astra Zeneca
  • Kyowa Kirin
  • Fresenius
  • PTC
  • BeOne
  • Incyte
  • BioCryst
  • Eli Lilly
  • OM Pharma
  • Pharmanutra
  • Y-mAbs

Contact

Corporate Headquarters

Swixx Biopharma AG
Neuhofstrasse 5A
CH-6340 Baar
Switzerland
Tel. +41 41 5523 440
info@swixxbiopharma.com

Other Countries

Management Center

Hybernská 5, 11000 Praha 1
Czech Republic
Tel. +420 242 434 242
info@swixxbiopharma.com

Other pages powered by SWIXX

prevenFLU